Results 31 to 40 of about 23,536 (264)

Genotype resistance profiles in patients failing an NNRTI‐containing regimen, and modifications after stopping NNRTI therapy [PDF]

Journal of Clinical Laboratory Analysis, 2002
AbstractResistance to non‐nucleoside reverse transcriptase inhibitors (NNRTIs) develops quickly and independently if they are used in combination with NRTIs or protease inhibitors (PIs) as rescue therapy, mainly due to the low genetic barrier of this class of drugs.
QUIROS ROLDAN, Maria Eugenia, Airoldi M, Moretti F, Fausti C, Pan A, CASARI, Salvatore, TORTI, Carlo, CASTELLI, Francesco, CAROSI, Giampiero   +8 more
openaire   +3 more sources

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

The Lancet HIV, 2017
Summary Background There is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries. We assessed the effectiveness
Andrew N. Phillips, V. Cambiano, F. Nakagawa, P. Revill, Michael R. Jordan, T. Hallett, Meg Doherty, A. De Luca, Jens D. Lundgren, M. Mhangara, T. Apollo, John W. Mellors, Brooke E. Nichols, Urvi M. Parikh, Deenan Pillay, Tobias F. Rinke de Wit, K. Sigaloff, D. Havlir, Daniel R. Kuritzkes, A. Pozniak, D. A. van de Vijver, Marco Vitoria, M. Wainberg, Elliot Raizes, S. Bertagnolio   +24 more
semanticscholar   +1 more source

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. [PDF]

PLoS ONE, 2012
BACKGROUND: The accumulation of mutations after long-lasting exposure to a failing combination antiretroviral therapy (cART) is problematic and severely reduces the options for further successful treatments.
Alexandra U Scherrer, Jürg Böni, Sabine Yerly, Thomas Klimkait, Vincent Aubert, Hansjakob Furrer, Alexandra Calmy, Matthias Cavassini, Luigia Elzi, Pietro L Vernazza, Enos Bernasconi, Bruno Ledergerber, Huldrych F Günthard, Swiss HIV Cohort Study (SHCS)   +13 more
doaj   +1 more source

High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up

AIDS Research and Therapy, 2019
High rates of non-nucleoside reverse transcriptase inhibitors (NNRTI) resistance was a key consideration in the WHO policies transitioning first-line regimens to include integrase inhibitors (dolutegravir [DTG]).
S. Rutstein, Jane S. Chen, J. Nelson, S. Phiri, W. Miller, M. Hosseinipour   +5 more
semanticscholar   +1 more source

Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting

AIDS Research and Therapy, 2007
Background Non-nucleoside reverse transcriptase inhibitor (NNRTI) with stavudine and lamivudine is widely used as the first-line antiretroviral therapy (ART) in resource-limited settings.
Watcharananan Siriorn, Malathum Kumthorn, Apisarnthanarak Anucha, Kiertiburanakul Sasisopin, Sungkanuparph Somnuek, Sathapatayavongs Boonmee   +5 more
doaj   +1 more source

Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells

Stem Cell Research & Therapy, 2022
Background To determine the effects of integrase inhibitor (INSTI) in comparison with non-INSTI-based regimens such as non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based regimens on cardiovascular disease (CVD) risk in HIV+ patients without ...
Adrian Farid Elzarki, Seshagiri Rao Nandula, Hassan Awal, Gary L. Simon, Sabyasachi Sen   +4 more
doaj   +1 more source

Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa.

PLoS Computational Biology, 2019
The scale-up of antiretroviral therapy (ART) in South Africa substantially reduced AIDS-related deaths and new HIV infections. However, its success is threatened by the emergence of resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTI ...
Anthony Hauser, Katharina Kusejko, Leigh F Johnson, Gilles Wandeler, Julien Riou, Fardo Goldstein, Matthias Egger, Roger D Kouyos   +7 more
doaj   +1 more source

Comparison of Three Different Anti-retroviral Regimens in Terms of Immunological and Virological Response

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018
Introduction: After introduction of highly active anti-retroviral treatment (HAART), the mortality and morbidity rates among HIV/AIDS patients have been reduced. CD4+ T cell and HIV RNA measurement is important in the follow-up during the treatment.
Ufuk SÖNMEZ, Sabri ATALAY, Hazal ALBAYRAK, Melda TÜRKEN, Şükran KÖSE   +4 more
doaj   +1 more source

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa

Journal of Acquired Immune Deficiency Syndromes, 2017
Objective: To determine drug resistance mutation (DRM) patterns in a large cohort of patients failing nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy regimens in programs without routine viral load (VL ...
C. Kityo, Jennifer A. Thompson, I. Nankya, Anne Hoppe, E. Ndashimye, C. Warambwa, I. Mambule, J. V. van Oosterhout, K. Wools-Kaloustian, S. Bertagnolio, Philippa J. Easterbrook, P. Mugyenyi, A. S. Walker, Nicholas I. Paton   +13 more
semanticscholar   +1 more source

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors

Biology, 2012
HIV-1 Reverse Transcriptase (RT) is a multifunctional enzyme responsible for the transcription of the RNA genome of the HIV virus into DNA suitable for incorporation within the DNA of human host cells. Its crucial role in the viral life cycle has made it
Peter V. Coveney, Paul Kellam, Benjamin A. Hall, David W. Wright   +3 more
doaj   +1 more source